-
-
In a post-hoc analysis, rasagiline, as an adjunct to levodopa, is both efficacious in reducing "off" time and well-tolerated in individuals older than 70 years with moderate-to-advanced Parkinson's disease.
-
Antihypertensive treatment reduces the incidence of headache compared to placebo, but the magnitude of the effect differs between drug classes independent of the magnitude of blood pressure reduction. Dysautoregulation in the anterior and posterior circulation is associated with migraine with aura.
-
When a brain biopsy is being considered for a nonmalignant condition, the patients and the site of biopsy must be carefully selected to ensure the most useful results.
-
This paper reports on the findings of a systematic literature review on noise and noise-reduction strategies in the intensive care unit (ICU).
-
Arnold and colleagues at Barnes-Jewish Hospital in St. Louis performed a 6-year retrospective cohort study of patients with bronchoalveolar lavage (BAL) documented ventilator-associated pneumonia (VAP), diagnosed by accepted clinical and quantitative culture criteria, that was caused by either Pseudomonas aeruginosa (PA) and Acinetobacter baumannii(AB).
-
The intensive care unit (ICU) can be immensely stressful for caregivers and can lead to burnout that results from chronic emotional and interpersonal stressors in the environment.
-
Although current guidelines recommend delaying neuroprognostication during therapeutic hypothermia following resuscitation from cardiac arrest, this review of 55 consecutive patients so managed found that a "poor prognosis" designation was arrived at during the hypothermia period in most of them, including six patients who were eventually discharged with a favorable neurologic outlook.
-
Wunsch and associates describe two patients who suffered respiratory arrest requiring intubation and mechanical ventilation while receiving polymyxin B.
-
In this issue: Statins and diabetes risk; new treatment guideline for diabetes; new pertussis vaccine recommendation; antibiotics and rhinosinusitis; fluoroquinolones and cystitis; and FDA actions.
